CT image of pancreatic adenocarcinoma with liver metastases

Enrolling Clinical Trials: Combination Chemotherapy / Immunotherapy for Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

December 01, 2017

Researchers at the Abramson Cancer Center are participating in a multi-center clinical trial to determine the safety and benefit of an investigational anti-CD40 agonist antibody when added to the chemotherapeutics nab-paclitaxel and gemcitabine in patients with newly diagnosed resectable pancreatic ductal adenocarcinoma (PDA).




Share This Page: